UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
 
For the month of February 2020
 
Commission File Number 001-38367
 
SOL-GEL TECHNOLOGIES LTD.
(Translation of registrant’s name into English)
 
7 Golda Meir Street
Ness Ziona 7403650, Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F ☒           Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐


INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
 
On February 13, 2020, Sol-Gel Technologies Ltd. (the “Company”) issued a press release announcing positive topline results from its open-label, long-term safety study of Epsolay® for treatment up to 52 weeks.
 
Attached hereto and incorporated by reference in this Report on Form 6-K is the following exhibit:
 
 
This Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statement on Form F-3 (Registration No. 333-230564) and Registration Statement on Form S-8 (Registration No. 333-223915).


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
SOL-GEL TECHNOLOGIES LTD.
 
 
 
Date:  February 13, 2020
By:
/s/ Gilad Mamlok
 
 
Gilad Mamlok
 
 
Chief Financial Officer

 

 

 
 

Sol Gel Technologies (NASDAQ:SLGL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sol Gel Technologies Charts.
Sol Gel Technologies (NASDAQ:SLGL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sol Gel Technologies Charts.